Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 42 min ago
Peer-reviewedCC BY 4.0Infection

Shortening of central venous catheter time in men with hematological and oncological diseases for prevention of central venous catheter-related bloodstream infections: a target-trial-emulation study

  • Oliver Kriege1
  • Boris Böll2
  • Nicole Brüder3
  • Nicola Giesen4
  • Julia Lanznaster5
  • Susanne Mertins6
  • Antrea Minti7,8
  • Jan-Hendrik Naendrup2
  • Martin Schmidt-Hieber9
  • Ruth Seggewiss-Bernhardt10,11
  • Philipp Weber12
  • Kai Wille13
13 more authors
  • Jens Panse7,8
  • Marcus Hentrich14
  • Enrico Schalk15
  • Sabine Einhell
  • Sabine Einhell
  • Eva Fiegle
  • Pierre Kremer
  • Timo Schmitt
  • Sebastian Schulz
  • Christoph Schüssler
  • Daniela Tölle
  • Benedikt W. Pelzer
  • Judit Grans-Siebel
15 affiliations
  1. 1Department of Hematology and Medical Oncology, University Medical Center of the Johannes Gutenberg University Mainz, Langenbeckstr. 1, 55131 Mainz, Germany
  2. 2Department of Internal Medicine I, University Hospital of Cologne, Cologne, Germany
  3. 3Department of Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
  4. 4Department of Hematology, Oncology and Palliative Care, Robert Bosch Hospital, Stuttgart, Germany
  5. 5Department of Internal Medicine II, Passau Hospital, Passau, Germany
  6. 6Department of Internal Medicine II, Schwarzwald – Baar – Klinikum, Villingen-Schwenningen, Germany
  7. 7Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany
  8. 8Center for Integrated Oncology (CIO), Aachen, Bonn, Cologne, Düsseldorf (ABCD), Germany
  9. 9Clinic of Hematology, Oncology, Pneumology, Nephrology and Diabetology, Medical University Lausitz – Carl Thiem (MUL-CT), Cottbus, Germany
  10. 10Department of Hematology and Oncology, Sozialstiftung Bamberg, Bamberg, Germany
  11. 11Comprehensive Cancer Center Mainfranken (CCC MF), University Hospital of Würzburg, Würzburg, Germany
  12. 12Department of Internal Medicine I, Klinikum Mutterhaus der Borromaerinnen, Trier, Germany
  13. 13Oncology, Hemostaseology and Palliative Care, University Clinic for Hematology, University of Bochum, Minden, Germany
  14. 14Department of Hematology and Oncology, Red Cross Hospital Munich, Munich, Germany
  15. 15Medical Faculty, Department of Hematology, Oncology, Cell and Radiation Therapy, Otto von Guericke University Magdeburg, Magdeburg, Germany
Read full textPDFDOICite

Abstract

Purpose

In patients with hematological malignancies and central venous catheters (CVC) men have a higher risk for CVC related bloodstream infections (CRBSI) than women. Hence, preventive strategies such as earlier CVC removal may reduce the overall CRBSI (oCRBSI) rate.

Methods

A randomized simulation using data from a CVC registry was performed. Data were derived from unselected patients with hematological or oncological diseases and a CVC. Patients were randomized to an experimental (EXP-G) or control group (CON-G). For the men in the EXP-G, one-day increments of an earlier CVC removal were simulated based on actual data and compared to men in the CON-G without simulation. The primary endpoint was oCRBSI rate.

Results

Underlying diseases were mainly hematological malignancies (87.3%). In the male patients with a median CVC in situ time of 13 days, the oCRBSI rate was 7.3% (103/1408), with 7.3% (53/729) in the EXP-G and 7.4% (50/679) in the CON-G. In the EXP-G, simulated shortening of CVC time by 1 day in men resulted in an oCRBSI rate of 5.2% compared with 7.4% in the CON-G (p = 0.12). Shortening CVC time by 2 days led to an oCRBSI rate of 4% (p = 0.008); the corresponding median CVC time was 11 days. A 3-day shortening further to 10 days reduced the oCRBSI rate to 2.7% (p < 0.001). Women from the same registry showed a 3.3% (30/920) oCRBSI rate after 12 days.

Conclusion

In conclusion, shortening the CVC dwell time in men by 2 or 3 days, corresponding to a CVC duration of 10–11 days, reduces the CRBSI rate in men and mitigates the higher risk, compared to women.

Clinical Trial Registration: SECRECY (Study to Evaluate Central Venous Catheter-related Infections in Hematology and Oncology) was registered within the German Clinical Trial Register (DRKS; no. DRKS00006551) on 29 September 2014.

Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s15010-026-02888-7.

Related

  1. Performance of Direct Identification and EUCAST Rapid Antimicrobial Susceptibility Testing in Bloodstream Infections Using Sepsityper® and Disk Diffusion Methods
    Diagnostics (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Bloodstream Infections in Patients with Malignancy: Microbiological Epidemiology, Antimicrobial Resistance, and Factors Associated with Mortality in a Nine-Year Single-Center Retrospective Cohort
    Cihan Yeşil, Cemile Arslan Yeşil, Ferhat Yılmaz +2
    Diagnostics (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Early best available antibiotic therapy for multidrug-resistant gram-negative bloodstream infections: a target trial emulation
    Luca Mezzadri, Wei Cong Tan, Xinxin Hao +102
    eClinicalMedicinePeer-reviewedCC BY 4.0General medicineCrossref
  4. Clinical correlates of the Haemoglobin to Red Cell Distribution Width ratio in bacterial bloodstream infections and concomitant kidney dysfunction.
    John Nzobokela, David Chisompola, Jay Chibinga +3
    BMC research notesPeer-reviewedCC BY-NC-NDFull textEpidemiology & public healthEurope PMCPMC
  5. Clinical correlates for fluconazole resistance in Candida bloodstream infections.
    Zihuan Li, Tian Wang, Mengdie Zhang +5
    Frontiers in public healthPeer-reviewedCC BYFull textInfectious diseaseEurope PMCCrossref

Cite

BibTeXRIS
BibTeX
@article{kriege2026shortening,
  title = {{Shortening of central venous catheter time in men with hematological and oncological diseases for prevention of central venous catheter-related bloodstream infections: a target-trial-emulation study}},
  author = {Oliver Kriege and Boris Böll and Nicole Brüder and Nicola Giesen and Julia Lanznaster and Susanne Mertins and Antrea Minti and Jan-Hendrik Naendrup and Martin Schmidt-Hieber and Ruth Seggewiss-Bernhardt and Philipp Weber and Kai Wille and Jens Panse and Marcus Hentrich and Enrico Schalk and Sabine Einhell and Sabine Einhell and Eva Fiegle and Pierre Kremer and Timo Schmitt and Sebastian Schulz and Christoph Schüssler and Daniela Tölle and Benedikt W. Pelzer and Judit Grans-Siebel},
  journal = {Infection},
  year = {2026},
  month = jul,
  doi = {10.1007/s15010-026-02888-7},
  url = {https://doi.org/10.1007/s15010-026-02888-7},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Shortening of central venous catheter time in men with hematological and oncological diseases for prevention of central venous catheter-related bloodstream infections: a target-trial-emulation study
AU  - Oliver Kriege
AU  - Boris Böll
AU  - Nicole Brüder
AU  - Nicola Giesen
AU  - Julia Lanznaster
AU  - Susanne Mertins
AU  - Antrea Minti
AU  - Jan-Hendrik Naendrup
AU  - Martin Schmidt-Hieber
AU  - Ruth Seggewiss-Bernhardt
AU  - Philipp Weber
AU  - Kai Wille
AU  - Jens Panse
AU  - Marcus Hentrich
AU  - Enrico Schalk
AU  - Sabine Einhell
AU  - Sabine Einhell
AU  - Eva Fiegle
AU  - Pierre Kremer
AU  - Timo Schmitt
AU  - Sebastian Schulz
AU  - Christoph Schüssler
AU  - Daniela Tölle
AU  - Benedikt W. Pelzer
AU  - Judit Grans-Siebel
PY  - 2026
DA  - 2026/07/10
JO  - Infection
DO  - 10.1007/s15010-026-02888-7
UR  - https://doi.org/10.1007/s15010-026-02888-7
AB  - Purpose  In patients with hematological malignancies and central venous catheters (CVC) men have a higher risk for CVC related bloodstream infections (CRBSI) than women. Hence, preventive strategies such as earlier CVC removal may reduce the overall CRBSI (oCRBSI) rate.  Methods  A randomized simulation using data from a CVC registry was performed. Data were derived from unselected patients with hematological or oncological diseases and a CVC. Patients were randomized to an experimental (EXP-G) or control group (CON-G). For the men in the EXP-G, one-day increments of an earlier CVC removal were simulated based on actual data and compared to men in the CON-G without simulation. The primary endpoint was oCRBSI rate.  Results  Underlying diseases were mainly hematological malignancies (87.3%). In the male patients with a median CVC in situ time of 13 days, the oCRBSI rate was 7.3% (103/1408), with 7.3% (53/729) in the EXP-G and 7.4% (50/679) in the CON-G. In the EXP-G, simulated shortening of CVC time by 1 day in men resulted in an oCRBSI rate of 5.2% compared with 7.4% in the CON-G (p = 0.12). Shortening CVC time by 2 days led to an oCRBSI rate of 4% (p = 0.008); the corresponding median CVC time was 11 days. A 3-day shortening further to 10 days reduced the oCRBSI rate to 2.7% (p < 0.001). Women from the same registry showed a 3.3% (30/920) oCRBSI rate after 12 days.  Conclusion  In conclusion, shortening the CVC dwell time in men by 2 or 3 days, corresponding to a CVC duration of 10–11 days, reduces the CRBSI rate in men and mitigates the higher risk, compared to women.  Clinical Trial Registration: SECRECY (Study to Evaluate Central Venous Catheter-related Infections in Hematology and Oncology) was registered within the German Clinical Trial Register (DRKS; no. DRKS00006551) on 29 September 2014.  Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s15010-026-02888-7.
SN  - 0300-8126
SN  - 1439-0973
ER  -